124 related articles for article (PubMed ID: 11811984)
1. Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity.
Friry C; Feliciangeli S; Richard F; Kitabgi P; Rovere C
Biochem Biophys Res Commun; 2002 Feb; 290(4):1161-8. PubMed ID: 11811984
[TBL] [Abstract][Full Text] [Related]
2. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation.
Ernst A; Hellmich S; Bergmann A
Peptides; 2006 Jul; 27(7):1787-93. PubMed ID: 16519961
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis and posttranslational processing of the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line. Effect of dexamethasone.
de Nadai F; Rovere C; Bidard JN; Laur J; Martinez J; Cuber JC; Kitabgi P
Endocrinology; 1993 Apr; 132(4):1614-20. PubMed ID: 8462460
[TBL] [Abstract][Full Text] [Related]
4. Pro-neurotensin/neuromedin N expression and processing in human colon cancer cell lines.
Rovère C; Barbero P; Maoret JJ; Laburthe M; Kitabgi P
Biochem Biophys Res Commun; 1998 May; 246(1):155-9. PubMed ID: 9600085
[TBL] [Abstract][Full Text] [Related]
5. Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases.
Kitabgi P
Peptides; 2006 Oct; 27(10):2508-14. PubMed ID: 16904237
[TBL] [Abstract][Full Text] [Related]
6. Impaired processing of brain proneurotensin and promelanin-concentrating hormone in obese fat/fat mice.
Rovere C; Viale A; Nahon J; Kitabgi P
Endocrinology; 1996 Jul; 137(7):2954-8. PubMed ID: 8770919
[TBL] [Abstract][Full Text] [Related]
7. Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line.
Bidard JN; de Nadai F; Rovere C; Moinier D; Laur J; Martinez J; Cuber JC; Kitabgi P
Biochem J; 1993 Apr; 291 ( Pt 1)(Pt 1):225-33. PubMed ID: 8471039
[TBL] [Abstract][Full Text] [Related]
8. Evidence that PC2 is the endogenous pro-neurotensin convertase in rMTC 6-23 cells and that PC1- and PC2-transfected PC12 cells differentially process pro-neurotensin.
Rovère C; Barbero P; Kitabgi P
J Biol Chem; 1996 May; 271(19):11368-75. PubMed ID: 8626691
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases.
Kitabgi P
Peptides; 2006 Oct; 27(10):2515-22. PubMed ID: 16904239
[TBL] [Abstract][Full Text] [Related]
11. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2.
Gendron L; Perron A; Payet MD; Gallo-Payet N; Sarret P; Beaudet A
Mol Pharmacol; 2004 Dec; 66(6):1421-30. PubMed ID: 15361549
[TBL] [Abstract][Full Text] [Related]
12. Species differences in brain pre-pro-neurotensin/neuromedin N mRNA distribution: the expression pattern in mice resembles more closely that of primates than rats.
Smits SM; Terwisscha van Scheltinga AF; van der Linden AJ; Burbach JP; Smidt MP
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):22-8. PubMed ID: 15193419
[TBL] [Abstract][Full Text] [Related]
13. Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress.
Carraway RE; Hassan S
Regul Pept; 2007 Jun; 141(1-3):140-53. PubMed ID: 17289170
[TBL] [Abstract][Full Text] [Related]
14. Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells.
Carraway RE; Hassan S; Cochrane DE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):93-107. PubMed ID: 16406549
[TBL] [Abstract][Full Text] [Related]
15. Characterization and autoradiographic localization of neurotensin binding sites in human sigmoid colon.
Azriel Y; Burcher E
J Pharmacol Exp Ther; 2001 Jun; 297(3):1074-81. PubMed ID: 11356931
[TBL] [Abstract][Full Text] [Related]
16. Internalization-dependent regulation of HT29 cell proliferation by neurotensin.
Navarro V; Martin S; Mazella J
Peptides; 2006 Oct; 27(10):2502-7. PubMed ID: 16870305
[TBL] [Abstract][Full Text] [Related]
17. Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines.
Kitabgi P
Results Probl Cell Differ; 2010; 50():85-96. PubMed ID: 19862492
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells.
Carraway RE; Hassan S; Dobner PR
Regul Pept; 2008 Apr; 147(1-3):96-109. PubMed ID: 18313772
[TBL] [Abstract][Full Text] [Related]
19. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
20. On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.
Seebach D; Lukaszuk A; Patora-Komisarska K; Podwysocka D; Gardiner J; Ebert MO; Reubi JC; Cescato R; Waser B; Gmeiner P; Hübner H; Rougeot C
Chem Biodivers; 2011 May; 8(5):711-39. PubMed ID: 21560227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
